Medical Uses of Opioids: Indications, Mechanisms & Risk Mitigation
Therapeutic Indications for Opioid Agonists
Opioids (μ-receptor agonists) remain essential medicines for specific indications when benefits outweigh risks. Use requires structured risk assessment, informed consent, and multimodal integration.
FDA-Approved / Guideline-Supported Indications
| Indication | Typical Agents & Routes | Key Considerations |
|---|---|---|
| Acute Severe Pain (trauma, surgery, burns, sickle cell crisis) | Morphine, hydromorphone, fentanyl IV; oxycodone, hydrocodone PO | Short-course (3–7 d); scheduled → PRN taper; multimodal (acetaminophen, NSAID, regional, gabapentinoid) |
| Cancer Pain (WHO Analgesic Ladder Step 3) | Morphine, oxycodone, fentanyl (transdermal), methadone, hydromorphone | Around-the-clock + breakthrough; no arbitrary dose ceiling; reassess q visit; laxative prophylaxis |
| Palliative / End-of-Life Dyspnea & Pain | Morphine SC/IV, fentanyl patch, hydromorphone PCA | Goal: comfort; respiratory depression rare at therapeutic doses in opioid-tolerant; double effect principle |
| Procedural Sedation / Anesthesia Adjunct | Fentanyl, remifentanil, sufentanil, alfentanil IV | Anesthesia-trained provider; monitoring (capnography, SpO₂); reversal (naloxone) available |
| Refractory Chronic Cough | Low-dose morphine sulfate PO (5–10 mg q4–6h) | Specialist referral; failed antitussives; monitor for sedation/constipation |
| Severe Diarrhea (Palliative / Short Bowel) | Loperamide (μ-agonist, poor CNS penetration), tincture of opium, diphenoxylate/atropine | Loperamide first-line; opioid only if refractory; avoid in infectious colitis |
| Neonatal Abstinence Syndrome (NAS) | Morphine, methadone, buprenorphine (sublingual) | Protocolized wean (Finnegan scoring); non-pharm care first |
